novo nordisk pfizer - Search News

Pfizer sues Metsera, Novo Nordisk

Novo Nordisk downgrades sales outlook again amid bidding war with Pfizer for Metsera

Another quarterly earnings announcement from Novo Nordisk and another downgrade to earnings guidance from the Danish pharmaceuticals company, the fourth this year. The shares of Novo Nordisk have halved this year as a consequence and what was the largest stock in Europe by market capitalization at one point a few months ago is now the eighth.

· 1d · on MSN

Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer

· 21h · on MSN

Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight

· 1d

Pfizer and Novo Nordisk sweeten offers for Metsera as bidding war intensifies

Last week, Novo came over the top of an original Pfizer deal with Metsera with an up to $9bn offer for the biotech, sparking one of the most contentious bidding wars over a biotech in recent memory.

· 1d

Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, source says

· 1d

Eli Lilly, Novo reportedly nearing U.S. deals for obesity drug prices (update)

1hon MSN

Pfizer matches Novo bid for obesity biotech Metsera as takeover battle rages - FT

The U.S. drugmaker submitted its sweetened bid, which matches Novo’s offer from Tuesday, valuing Metsera at $86.20 a share, ahead of a deadline on Wednesday, keeping it in the race for the anti-obesity biotech, the Financial Times reported.

20h

Novo Nordisk's Medicare deal takes heat off Wegovy slowdown

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year profit and sales forecasts on Wednesday as sales growth slows, but investors cheered a better-than-expected Medicare pricing deal that helped lift the shares after an initial slide.

Devdiscourse

Pfizer and Novo Nordisk Lock Horns in Billion-Dollar Merger Battle

A Delaware judge denied Pfizer's attempt to halt Metsera from accepting Novo Nordisk's $10 billion offer. Although Novo faces antitrust challenges, both companies are fiercely bidding for Metsera in a battle for dominance over a potentially lucrative obesity drug market.